| |  Online-Ressource |
|---|
| Verfasst von: | Saadatian-Elahi, Mitra [VerfasserIn]  |
|---|
| | Horstick, Olaf [VerfasserIn] |
|---|
| | Breiman, Robert F. [VerfasserIn] |
|---|
| | Gessner, Bradford D. [VerfasserIn] |
|---|
| | Gubler, Duane J. [VerfasserIn] |
|---|
| | Louis, Jacques [VerfasserIn] |
|---|
| | Parashar, Umesh D. [VerfasserIn] |
|---|
| | Tapia, Roberto [VerfasserIn] |
|---|
| | Picot, Valentina [VerfasserIn] |
|---|
| | Zinsou, Jean-Antoine [VerfasserIn] |
|---|
| | Nelson, Christopher B. [VerfasserIn] |
|---|
| Titel: | Beyond efficacy |
|---|
| Titelzusatz: | the full public health impact of vaccines |
|---|
| Verf.angabe: | Mitra Saadatian-Elahi, Olaf Horstick, Robert F. Breiman, Bradford D. Gessner, Duane J. Gubler, Jacques Louis, Umesh D. Parashar, Roberto Tapia, Valentina Picot, Jean-Antoine Zinsou, Christopher B. Nelson |
|---|
| E-Jahr: | 2016 |
|---|
| Jahr: | 23 January 2016 |
|---|
| Umfang: | 9 S. |
|---|
| Fussnoten: | Gesehen am 07.05.2020 |
|---|
| Titel Quelle: | Enthalten in: Vaccine |
|---|
| Ort Quelle: | Amsterdam : Elsevier, 1983 |
|---|
| Jahr Quelle: | 2016 |
|---|
| Band/Heft Quelle: | 34(2016), 9, Seite 1139-1147 |
|---|
| ISSN Quelle: | 1873-2518 |
|---|
| Abstract: | There is an active discussion in the public health community on how to assess and incorporate, in addition to safety and measures of protective efficacy, the full public health value of preventive vaccines into the evidence-based decision-making process of vaccine licensure and recommendations for public health use. The conference “Beyond efficacy: the full public health impact of vaccines in addition to efficacy measures in trials” held in Annecy, France (June 22-24, 2015) has addressed this issue and provided recommendations on how to better capture the whole public health impact of vaccines. Using key examples, the expert group stressed that we are in the midst of a new paradigm in vaccine evaluation, where all aspects of public health value of vaccines beyond efficacy should be evaluated. To yield a wider scope of vaccine benefits, additional measures such as vaccine preventable disease incidence, overall efficacy and other outcomes such as under-five mortality or non-etiologically confirmed clinical syndromes should be assessed in addition to traditional efficacy or effectiveness measurements. Dynamic modelling and the use of probe studies should also be considered to provide additional insight to the full public health value of a vaccine. The use of burden reduction and conditional licensure of vaccines based on collection of outcome results should be considered by regulatory agencies. |
|---|
| DOI: | doi:10.1016/j.vaccine.2016.01.021 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1016/j.vaccine.2016.01.021 |
|---|
| | Volltext: http://www.sciencedirect.com/science/article/pii/S0264410X16000566 |
|---|
| | DOI: https://doi.org/10.1016/j.vaccine.2016.01.021 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Beyond vaccine efficacy |
|---|
| | Conference report |
|---|
| | Vaccine effectiveness |
|---|
| | Vaccine efficacy |
|---|
| | Vaccine preventable disease incidence |
|---|
| | Vaccine probe analysis |
|---|
| K10plus-PPN: | 1697649211 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Beyond efficacy / Saadatian-Elahi, Mitra [VerfasserIn]; 23 January 2016 (Online-Ressource)
